Greenphire Announces New London Office
News May 07, 2013
Greenphire announced an expansion into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and is designed to support the increasing global demand for Greenphire’s products and services.
The expansion reflects the commercial and operational success Greenphire has enjoyed in the last two years. Both global payment technology platforms for Patient and Investigator payments have seen increased adoption within the life sciences industry and the new office in London will play a critical role in continuing to build on the growth Greenphire has experienced.
Sam Whitaker, Founder and CEO, comments “We are excited to execute on this key part of our 2013 strategic plan. Establishing our presence in Europe allows us to support our Enterprise clients in those areas where they conduct research and development, facilitates stronger support of the many clinical investigators conducting research on behalf of biopharmaceutical companies and provides a base from which we can grow our commercial presence in Europe.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE